key: cord-0738953-mx9bxwzr
authors: Pickens, Chiagozie; Wunderink, Richard G.; Qi, Chao; Mopuru, Haritha; Donnelly, Helen; Powell, Kimberly; Sims, Matthew D
title: A multiplex polymerase chain reaction assay for antibiotic stewardship in suspected pneumonia()
date: 2020-08-16
journal: Diagn Microbiol Infect Dis
DOI: 10.1016/j.diagmicrobio.2020.115179
sha: f6b7250a448d07573b8e93db56d2341a425a8554
doc_id: 738953
cord_uid: mx9bxwzr

BACKGROUND: Multiplexed molecular rapid diagnostic tests (RDTs) may allow for rapid and accurate diagnosis of the microbial etiology of pneumonia. However, little data are available on multiplexed RDTs in pneumonia and their impact on clinical practice. METHODS: This retrospective study analyzed 659 hospitalized patients for microbiological diagnosis of suspected pneumonia. RESULTS: The overall sensitivity of the Unyvero LRT Panel was 85.7% (95% CI 82.3–88.7) and the overall specificity was 98.4% (95% CI 98.2–98.7) with a negative predictive value of 97.9% (95% CI 97.6–98.1). The LRT Panel result predicted no change in antibiotics in 12.4% of cases but antibiotic de-escalation in 65.9% (405/615) of patients, of whom 278/405 (69%) had unnecessary MRSA coverage and 259/405 (64%) had unnecessary P. aeruginosa coverage. INTERPRETATION. In hospitalized adults with suspected pneumonia, use of an RDT on respiratory samples can allow for early adjustment of initial antibiotics, most commonly de-escalation.

Pneumonia remains a leading cause of hospital admissions and is associated with substantial morbidity, mortality, healthcare costs, and days of work lost. 1 Community-acquired pneumonia (CAP) is estimated to cause ~1.5 million hospitalizations and ~100,000 deaths in the US each year, 2 equating to an aggregate cost of nearly $9.5 billion for 960,000 hospital stays. 3, 4 Hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), is the most common healthcare-associated infection. 5 Despite clinical advances, the burden of pneumonia on the healthcare system continues to increase, with hospitalization rates for pneumonia increasing by 35% due to Klebsiella spp., 23% due to Pseudomonas spp., and 23% due to Staphylococcus aureus between 2001 and 2011. 6 An aging population, 7 poor sensitivity diagnostic tools, [8] [9] [10] prolonged courses of empiric antibiotics, 11 and the emergence of antimicrobial resistance 12 are all contributing to the persistent and increasing burden of pneumonia.

A hospitalized patient with suspected pneumonia is generally treated empirically. Empiric treatment recommendations in CAP, HAP, and VAP guidelines are based on risk factors for the specific pathogens seen in each form of pneumonia and are consistently associated with overtreatment. [13] [14] [15] Empiric treatment of CAP includes coverage of atypical but uncommon organisms, 16 and empiric antibiotic decisions are even more difficult for HAP/VAP due to other common antibiotic-resistant pathogens. Moreover, empiric treatment of both CAP and HAP/VAP focuses on MRSA and Pseudomonas coverage. 17 Subsequent tailoring of antibiotics is recommended to treat the specific etiology depending on the microbiological diagnosis; 18 however, the turnaround time for a final respiratory culture result can be upwards of 72 hours, during which time patients continue to receive empiric antibiotics. In addition, respiratory cultures are often negative due to their relatively poor sensitivity, particularly J o u r n a l P r e -p r o o f when obtained after initiation of antibiotic therapy, and can miss important pathogens when concealed by the growth of multiple organisms in culture. [8] [9] [10] These limitations of respiratory microbiological culture make effective antibiotic stewardship, defined as "coordinated interventions designed to improve and measure the appropriate use of antimicrobials by promoting the selection of optimal antimicrobial drug regimen, dose, duration of therapy, and route of administration", difficult. 19 As of September 2019, the Centers for Medicare and Medicaid Services now require US hospitals to implement antibiotic stewardship programs, highlighting the need for more appropriate antibiotic use. Antibiotic stewardship aims to minimize broad antibiotic use, which is associated with longer lengths of hospital stay, higher morbidity and mortality, higher hospital costs, nephrotoxicity, and nosocomial infections. 20-22 Guideline-driven empirical therapy for pneumonia with broad-spectrum antibiotics and the lag time to definitive microbiological diagnosis mean that (i) de-escalation cannot be performed quickly, making the use of inappropriate antibiotics more likely; and (ii) the prolonged use of broad-spectrum antibiotics promotes the development of antimicrobial resistance. 23-25 Therefore, an urgent need exists for the rapid detection of the causative pathogen in pneumonia in order to tailor antibiotics and encourage appropriate antibiotic stewardship.

Rapid diagnostic tests (RDTs) that reduce diagnostic turnaround times from days to hours can address some of the aforementioned clinical challenges. The 2019 Infectious Diseases Society of America CAP guidelines acknowledged the need for rapid, cost-effective, accurate tests to improve directed antibiotic therapy. 26 This crisis has led to a recommendation that antimicrobial prescriptions in high-income countries should be made only when supported by rapid diagnostic evidence, where such tests are available. 27 However, the majority of current RDTs for pneumonia only detect a single organism, 28 and experiences with high-sensitivity RDTs developed for malaria and tuberculosis in resource-poor settings have given rise to J o u r n a l P r e -p r o o f concerns that false positive results may result in overtreatment. [29] [30] [31] However, data on the clinical application and impact of a new generation of highly multiplexed RDTs, which detect multiple organisms in a single respiratory sample by molecular testing, are lacking.

The Unyvero Lower Respiratory Tract (LRT) Panel is an RDT that uses multiplex polymerase chain reaction (PCR) to identify 20 causative agents of severe lower respiratory tract infections (LRTIs) and ten antibiotic resistance determinants in clinical specimens. Using patients enrolled at two of the clinical sites for NCT01922024, a large noninterventional multicenter study that determined the operating characteristics of the Unyvero LRT Panel, we predicted the impact of Unyvero LRT Panel RDT results on adjustment of empiric antibiotic regimens in hospitalized patients with suspected pneumonia. other microbiologic tests; and discharge disposition were retrieved from the EMR.

The Unyvero LRT Panel is an RDT specifically designed for the detection of LRTIs.

Specimens were processed with the Unyvero LRT Panel assay as per the manufacturer's instructions and as described previously. 32,33 Organisms detected in the assay are shown in Table 1 . De-escalation and expansion favored, where multiple antibiotics were used and one drug was too broad while the other was too narrow, e.g., LRT Panel reported P. aeruginosa but the empiric antibiotic regimen was vancomycin (too broad) and ceftriaxone (too narrow); (5) Initiate antibiotics, where antibiotics were not initiated at the time of testing but an organism J o u r n a l P r e -p r o o f was identified by the LRT Panel. Results from the LRT Panel were not available to the treating clinician during the study.

Results were analyzed using descriptive statistics. For sensitivity and specificity calculations, routine culture was considered to be the gold standard. All statistical analyses were performed in SPSS v21 (IBM Statistics Inc., Chicago, IL).

Six-hundred and fifty-nine unique samples were enrolled in NCT01922024 at the two hospital systems. Study IDs were unavailable for 39 samples, and five samples had culture data but no antibiotic use data. Thus, 659 samples were available for determining the assay operating characteristics, 620 samples were available for concordance analysis, and 615 samples for antibiotic change analysis. Three-hundred and ninety-five samples were nonbronchoscopic or bronchoscopic BALs and 225 samples were ETAs obtained from patients in intensive care units and chronic ventilator units of the included hospitals.

Compared to the bacterial culture standard, the sensitivity, specificity, positive predictive value, and negative predictive value of the Unyvero LRT Panel in this patient population are shown in Table 2 . While the sensitivity varied for different organisms, the specificity was uniformly high (96.5-99.5%). The overall sensitivity of the Unyvero LRT Panel was 85.7% (95% CI 82.3-88.7) and the overall specificity was 98.4% (95% CI 98.2-98.7). Accordingly, the assay had a very high negative predictive value of 97.9% (95% CI 97.6-98.1). This J o u r n a l P r e -p r o o f compared favorably to a 91.4% sensitivity and 99.5% specificity for pathogen detection in the original nine-center study (ClinicalTrials.gov: NCT01922024), which determined operating characteristics using culture plus an independent PCR test as the gold standard for common pathogens, rather than culture alone.

The concordance between the Unyvero LRT Panel and culture results is reported in Table 3 .

According to our criteria, 75.0% of results were concordant, 9.2% were discordant, and 15.8% were both concordant and discordant. Of the discordant results, ~4% each were due to either LRT Panel negative/culture positive discordance or vice versa, suggesting that the LRT panel and culture misclassified similar numbers of cases for the major organisms responsible for LRTIs.

Having determined the organism and mecA status by the LRT Panel, we next predicted changes to antibiotic regimens based on the published guidelines for treatment of CAP and HAP (Figure 1) . 17, 26 Reassured by the excellent negative predictive value of the LRT panel, we determined that if MRSA or P. aeruginosa were not detected by the panel, then anti-MRSA and/or anti-pseudomonal therapies were not indicated.

The predicted changes to antibiotic therapy based on the LRT Panel are shown in Table 4 . Of the non-panel organisms found on culture ( Table 6) , 56% (46/79) were common oropharyngeal colonizing organisms that generally do not necessitate antibiotic escalation, and a further 28% (22/79) were organisms that would have been covered even with empiric treatment that removed MRSA and Pseudomonas coverage.

The laboratory diagnosis of LRTIs is predominantly based on microbiological cultures, introducing delays and the prolonged use of empiric, broad-spectrum antibiotic therapy in large numbers of patients. Antibiotic resistance is a severe and increasing problem J o u r n a l P r e -p r o o f worldwide, mandating the increased use of improved RDTs to reduce antibiotic administration and increase the use of specific antimicrobial therapies. 35, 36 Also, in consideration of the current global COVID-19 pandemic, concerns about secondary bacterial infections in hospitalized COVID-19 patients have given rise to the need for timely and appropriate diagnosis of pneumonia to address the over and under-treatment of patients, enabling healthcare providers to practice better antibiotic stewardship, and helping to limit resistance and the development of super-bugs. 37 Rapid multiplex RDTs may play a critical role in this crisis setting. Rapid molecular techniques such as the Unyvero LRT Panel are a promising tool to help guide appropriate therapy and de-escalation from broad-spectrum antibiotic therapy in patients with suspected pneumonia. 28,38 However, like any new medical technology, their potential clinical impact requires testing in clinical practice, and data on multiplex assays in particular are lacking. Here we analyzed the potential impact on antibiotic use in patients with suspected pneumonia with implementation of the Unyvero LRT Panel using data from a non-interventional study that originally evaluated the operating characteristics of the assay.

The overall sensitivity (85.7%) and specificity (98.4%) of the assay for organism detection in our mixed population of BALF and ETA samples were consistent with previous reports for this (88.8% and 94.9% 33 ) and another (90% and 97.4% 33 ) FDA-approved multiplex LRTI assay and comparable to the sensitivities and specificities reported for traditional ETA and BAL culture. 39 The LRT Panel results could have changed the choice of antibiotic used in the majority of cases, potentially leading to more effective antibiotic stewardship both in terms of regimen and duration. In 66% of cases, the initial antibiotic regimen was too broad for the pathogen identified by the LRT Panel and subsequent culture, consistent with a recent report in the critical care setting that multiplex PCR for respiratory pathogens would alter the antibiotic choice earlier in >50% of cases. 32 Contrary to previous concerns that RDTs may lead to overtreatment, 29-31 our data suggest that implementation of this RDT would de-escalate antibiotic use in the majority of cases. Even in cases where the LRT Panel result was negative for any organism, initial empiric antibiotic regimens usually still included anti-MRSA and antipseudomonal drugs. Conversely, in cases where the organism identified by the LRT panel was missed by culture, the patient was still usually covered by the empiric antibiotic regimen.

In this scenario, LRT results may potentially prevent inappropriate de-escalation.

A recent study of the BioFire FilmArray Pneumonia panel concluded that the panel could also allow antibiotic adjustment in 71% of cases including discontinuation or de-escalation in 48% of patients. 44 Pneumonia Panel provides semi-quantitative results using four different bin categories corresponding to 10 4 , 10 5 , 10 6 , or ≥10 7 copies/mL while the LRT Panel does not. Correlations to quantitative culture results reported as CFU/mL are however difficult, and agreement rates may be variable between organisms and in different specimen types; and concordance may be low, especially at lower CFU/mL densities. 45 The role of reporting semi-quantitative PCR results has yet to be defined in clinical practice.

Our evaluations regarding antibiotic escalation and de-escalation were based on the assumption that pneumonia was the most likely source of infection, as the study had enrolled This study has a number of limitations. We constructed a hypothetical estimate of the utility of the test, assuming 100% compliance with the assay and its results, which is unlikely to be achievable in practice. The decision to alter antimicrobial therapy was based on clinical guidelines, so mainly exploited results from two of the 20 organism targets and only two resistance markers, mecA and carbapenemase enzymes; it is possible that the negative predictive value for the detection of phenotypic resistance could be lower depending on prevalence of non-panel resistance mechanisms. 46 Whether these potential false-negative and false-positive molecular results will degrade the utility of the assay awaits a prospective interventional study performed at multiple sites. The exclusion of expectorated sputum from the analysis may also have increased the specificity of the test for pathogens causing true disease.

Application of this multiplexed LRTI rapid diagnostic test would most commonly predict adjustment to antibiotic prescribing for patients in whom MRSA or P. aeruginosa were unlikely to be the causative organism. Given the consistently high negative predictive value of the RDT and that mecA is the central determinant of MRSA, 34 even with the caveats of this study, our findings suggest that implementation of a multiplexed LRTI RDT is likely to alter the antibiotic management of significant numbers patients presenting with suspected pneumonia. When coupled with antimicrobial stewardship programs, rapid tests that identify organisms in respiratory samples can optimize antimicrobial utilization and patient outcomes. J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f 

Clinical and economic burden of community-acquired pneumonia in the Medicare fee-for-service population

Adults Hospitalized With Pneumonia in the United States: Incidence, Epidemiology, and Mortality

Incidence and cost of pneumonia in Medicare beneficiaries

Trends in healthcare utilization and costs associated with pneumonia in the United States during

Changes in Prevalence of Health Care-Associated Infections in U.S. Hospitals

Trends in pneumonia mortality rates and hospitalizations by organism

Infection in an aging population

A comparison of induced and expectorated sputum for the microbiological diagnosis of community acquired pneumonia

Value of routine microbial investigation in community-acquired pneumonia treated in a tertiary care center

Community-acquired pneumonia requiring hospitalization among US adults

A multicentre stewardship initiative to decrease excessive duration of antibiotic therapy for the treatment of communityacquired pneumonia

Impact on Morbidity, Mortality, and Length of Stay of Hospital-Acquired Infections by Resistant Microorganisms

Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: an observational, multicentre cohort study

Guideline-concordant therapy and outcomes in healthcare-associated pneumonia

Evaluation of the 2016 Infectious Diseases Society of America/American Thoracic Society Guideline Criteria for Risk of Multidrug-Resistant Pathogens in Patients with Hospital-acquired and Ventilatorassociated Pneumonia in the ICU

A worldwide perspective of atypical pathogens in community-acquired pneumonia

Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective

Community-Acquired Pneumonia Due to Multidrug-and Non-Multidrug-Resistant Pseudomonas aeruginosa

Antibiotic resistance: the hidden threat lurking behind Covid-19

New and novel rapid diagnostics that are impacting infection prevention and antimicrobial stewardship

Bronchoscopic diagnosis of pneumonia

Usefulness of quantitative endotracheal aspirate cultures in intensive care unit patients with suspected pneumonia

Evaluation of a Novel Multiplex PCR Panel Compared to Quantitative Bacterial Culture for the Diagnosis of Lower Respiratory Tract Infections

Contribution of blinded, protected quantitative specimens to the diagnostic and therapeutic management of ventilatorassociated pneumonia

Endotracheal aspirate and bronchoalveolar lavage fluid analysis: interchangeable diagnostic modalities in J o u r n a l P r e -p r o o f Journal Pre-proof suspected ventilator-associated pneumonia?

Practical Comparison of the BioFire FilmArray Pneumonia Panel to Routine Diagnostic Methods and Potential Impact on

Antimicrobial Stewardship in Adult Hospitalized Patients with Lower Respiratory Tract Infections

Rapid syndromic molecular testing in pneumonia: The current landscape and future potential

Evaluation of Empiric beta-Lactam Susceptibility Prediction among Enterobacteriaceae by Molecular beta-Lactamase Gene Testing

Abbreviations: TP, true positive; FN, false negative; FP, false positive; TN, true negative; PPV, positive predictive value

We would like to thank Nextgenediting for their assistance with review and revision of the manuscript.

J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f